#South Korea #Seoul #Seegene #HPV Genotyping #EUROGIN

Seegene Unveils Robust HPV Genotyping Solutions at EUROGIN 2025

Seegene Inc., a prominent player in PCR molecular diagnostics, made a significant impact at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) 2025 held in Porto, Portugal from March 16-19. Highlighting their commitment to improving cervical cancer screening, Seegene introduced its high-precision Human Papillomavirus (HPV) genotyping solutions aimed at enhancing the reliability of screening methods worldwide.

The Importance of Accurate HPV Screening

During this leading multidisciplinary HPV congress, Seegene showcased its extensive lineup of HPV diagnostic products designed to identify high-risk HPV types linked to cervical cancer. This innovation is critical as the accurate detection of such genotypes boosts the chances of early diagnosis, which is vital for effective treatment and improved patient outcomes. According to statistics provided by the World Health Organization (WHO), cervical cancer is the fourth most common cancer among women globally, emphasizing the urgent need for reliable screening solutions.

Self-Collection for Easier Screening

One of the standout features highlighted during the event was the self-sampling method for HPV testing. This approach allows individuals to collect their own samples, thus making the screening process more accessible and convenient. The symposium, which featured discussions led by clinical experts from Europe, explored strategies for integrating HPV testing into routine clinical practice. Experts recognized the potential of self-sampling in promoting broader adoption of HPV screening, which is essential in meeting global health objectives.

Daniel Shin, Executive Vice President and Chief Global Sales and Marketing Officer at Seegene, stated, "Seegene's HPV testing solutions are designed to deliver accurate diagnostics and reliable testing capabilities in real-world clinical environments." This commitment to quality and accessibility underlines Seegene's pivotal role in the ongoing fight against cervical cancer.

Continuous Participation in Global Discussions

Seegene’s presence at EUROGIN 2025 showcases its dedication to advancing HPV screening and enhancing genotyping methods. The company previously participated in AOGIN 2024, reinforcing its commitment to addressing cervical cancer through innovative diagnostics. By promoting dialogue among healthcare professionals, Seegene is contributing significantly to public health initiatives aimed at reducing the incidence of cervical cancer.

Aiming for Global Health Targets

The WHO’s 90-70-90 campaign sets ambitious targets for eliminating cervical cancer by 2030. These targets include achieving 90% vaccination coverage among girls by the age of 15, 70% of women screened with high-performance tests by the ages of 35 and 45, and ensuring that 90% of women identified with pre-cancer and invasive cancer receive treatment. Seegene’s advancements in HPV diagnostics play a crucial role in helping achieve these objectives, as reliable screening methods are foundational to effective prevention efforts.

Conclusion: A Future Focused on Preventing Cancer

With over 20 years of experience and a proven track record in providing PCR technologies, Seegene is well-positioned to lead advancements in medical diagnostics. The recent showcase at EUROGIN 2025 not only highlights the company’s innovative capabilities but also underscores its commitment to enhancing healthcare outcomes through improved cervical cancer screening. The future looks promising, with such initiatives paving the way for better health standards and cancer prevention strategies across the globe.